Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

NCT07421011 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome
Gallstone Disease
GERD
Biliary Dyskinesia
Postcholecystectomy Syndrome

Interventions

DRUG: Trimedat®

Sponsor

Valenta Pharm JSC